AstraZeneca Rejects 'incorrect' Reports On Covid Jab Efficacy In Elderly
Mohammad Ali (@ChaudhryMAli88) Published January 26, 2021 | 02:55 PM
Pharma giant AstraZeneca has defended the efficacy of its Covid-19 vaccine after media reports said the German government had doubts about its effectiveness among those over 65
Berlin, (APP - UrduPoint / Pakistan Point News - 26th Jan, 2021 ) :Pharma giant AstraZeneca has defended the efficacy of its Covid-19 vaccine after media reports said the German government had doubts about its effectiveness among those over 65.
The Handelsblatt economic daily reported Monday that Berlin had estimated the efficacy of the jab among over-65s was just eight percent, citing sources.
Bild also said that Berlin did not expect the vaccine -- developed with Oxford University and set to get the green light from the EU this week -- would receive a licence for use in the elderly, presenting a significant challenge to rollout plans in many countries.
But the company rejected the claims as erroneous.
"Reports that the AstraZeneca/Oxford vaccine efficacy is as low as eight percent in adults over 65 years are completely incorrect," the firm said in a statement late Monday.
"In November, we published data in The Lancet demonstrating that older adults showed strong immune responses to the vaccine, with 100 percent of older adults generating spike-specific antibodies after the second dose," it added.
Asked about the reports on Tuesday, German Health Minister Jens Spahn told public broadcaster ZDF that Berlin would wait to see the complete data from studies of the AstraZeneca vaccine before drawing any conclusions.
On that basis, decisions could be taken next week about "which age groups will be inoculated first with this vaccine".
The European Union issued an angry warning to AstraZeneca Monday over its unexpected delay in delivering millions of doses of its Covid-19 vaccine to the bloc.
Last Friday, the pharma giant said it would not meet its contractual delivery commitments to the European Union because of unexplained "reduced yields" in its European supply chain.
The European Union has currently authorised two vaccines for widespread distribution, manufactured by BioNTech/Pfizer and Moderna.
It was set to add the AstraZeneca vaccine to that list this week, on the understanding that it would be already on hand and available for immediate rollout.
Related Topics
Recent Stories
HEC reviews curricula for environmental sciences degree programme
ICC Asia looking forward to an action-packed Asia Cricket Week
Yuvraj Singh named ICC Men’s T20 World Cup 2024 Ambassador
Greece hands Olympic flame to 2024 Paris Games hosts
Two Kyiv hospitals evacuating over feared Russian strikes
World must act on neurotech revolution, say experts
Charles & Catherine's cancer diagnoses
Champions Alcaraz and Sabalenka through in Madrid Open
King Charles to resume some public duties during cancer treatment: palace
US defense chief announces $6 bn in security aid for Ukraine
Heavy rains cause damage to Spezand-Taftan railway track
Woman stabbed in Israel, attacker killed: police
More Stories From World
-
NFL will allow players to wear Guardian Cap helmets in games
3 hours ago -
Football: German Bundesliga table
3 hours ago -
Football: Italian Serie A result
3 hours ago -
Football: German Bundesliga results
3 hours ago -
US troops to leave Chad in second African state withdrawal
3 hours ago -
Plastics pollution may be solved without production cap: Canada minister
3 hours ago
-
Biden stalls on menthol cigarette ban fearing Black vote backlash
4 hours ago -
Champions Alcaraz and Sabalenka through in Madrid Open
4 hours ago -
6,000 French police to welcome Olympic torch amid bonus boost
4 hours ago -
Taiwan hit by several quakes, strongest reaching 6.1-magnitude
4 hours ago -
'Ballistic' Bairstow stars as Punjab pull off record T20 chase
4 hours ago -
Tennis: ATP/WTA Madrid Open results - 2nd update
4 hours ago